On 2015 Feb 06, Ryan Radecki commented:

Post-publication commentary: "Which Review of Tamiflu Data Do You Believe?"

Ever since its introduction, there have been skeptics regarding the utility of oseltamivir and other neuraminidase inhibitors for the treatment of influenza. Roche has profited tremendously off strategic stockpiling by many governments as a response to pandemic influenza – yet, nearly all the data comes from Roche-conducted trials, and the data has been persistently cloaked from independent review. This past year, after much strife and public shaming, the Cochrane Collaboration received some access to clinical trial reports to conduct an independent review. This review found, on average, adults receiving early treatment with oseltamivir benefited by reduction in symptom duration from 7 days to 6.3 days. No benefit was found for reduction in respiratory infectious complications or hospitalization, the truly critical need during influenza outbreaks.

However, a second group also conducted an independent review – the “Multiparty Group for Advice on Science”. Their results, based on an individual-patient meta-analysis, are published in the Lancet and offer similar – yet wildly different – conclusions....

http://www.emlitofnote.com/2015/02/which-review-of-tamiflu-data-do-you.html

On 2015 Feb 06, Ryan Radecki commented:

Post-publication commentary: "Which Review of Tamiflu Data Do You Believe?"

Ever since its introduction, there have been skeptics regarding the utility of oseltamivir and other neuraminidase inhibitors for the treatment of influenza. Roche has profited tremendously off strategic stockpiling by many governments as a response to pandemic influenza – yet, nearly all the data comes from Roche-conducted trials, and the data has been persistently cloaked from independent review. This past year, after much strife and public shaming, the Cochrane Collaboration received some access to clinical trial reports to conduct an independent review. This review found, on average, adults receiving early treatment with oseltamivir benefited by reduction in symptom duration from 7 days to 6.3 days. No benefit was found for reduction in respiratory infectious complications or hospitalization, the truly critical need during influenza outbreaks.

However, a second group also conducted an independent review – the “Multiparty Group for Advice on Science”. Their results, based on an individual-patient meta-analysis, are published in the Lancet and offer similar – yet wildly different – conclusions....

http://www.emlitofnote.com/2015/02/which-review-of-tamiflu-data-do-you.html